MTHFR Gene Polymorphism Is Associated With DNA Hypomethylation and Genetic Damage Among Benzene-Exposed Workers in Southeast China

2018 ◽  
Vol 60 (4) ◽  
pp. e188-e192 ◽  
Author(s):  
Jing-chao Ren ◽  
Yu-xia Wu ◽  
Zhenzhen Wu ◽  
Guang-hui Zhang ◽  
Hongjian Wang ◽  
...  
2008 ◽  
Vol 52 (8) ◽  
pp. 1374-1381 ◽  
Author(s):  
Kelly Cristina de Oliveira ◽  
Bianca Bianco ◽  
Ieda T. N. Verreschi ◽  
Alexis Dourado Guedes ◽  
Bianca Borsato Galera ◽  
...  

BACKGROUND: Dysfunctions in the folate metabolism can result in DNA hypomethylation and abnormal chromosome segregation. Two common polymorphisms of this enzyme (C677T and A1298C) reduce its activity, but when associated with aneuploidy studies the results are conflicting. The objective of the present study is to analyze the MTHFR gene polymorphisms in women with Turner Syndrome and in a control group, correlating the findings to the chromosomal aneuploidy. METHODS: The study comprised 140 patients with Turner Syndrome, of which 36 with chromosome mosaicism and 104 non-mosaics, and a control group of 209 fertile and healthy women without a history of any offspring with aneuploidy. Polymorphisms C677T and A1298C were studied by RFLP-PCR and the results were statistically analyzed. RESULTS: The frequency of genotypes MTHFR 677CC, 677CT and 677TT in the patients with Turner Syndrome and chromosome mosaicism was, respectively, 58.3%, 38.9% and 2.8%. Among the patients with non-mosaic Turner Syndrome, 47.1% presented genotype 677CC, 45.2% genotype 677CT, and 7.7% genotype 677TT. Among the 209 individuals of the control group, genotypes 677CC, 677CT and 677TT were found at the following frequencies: 48.3%, 42.1% and 9.6%, respectively. As for polymorphism A1298C, the patients with Turner Syndrome and chromosome mosaicism presented genotypes 1298AA, 1298AC and 1298CC at the following frequencies: 58.3%, 27.8% and 13.9%, respectively. Among the non-mosaic Turner Syndrome patients, genotype 1298AA was found in 36.5%, genotype 1298AC in 39.4%, and genotype 1298CC in 22.1%. In the control group, genotypes 1298AA, 1298AC and 1298CC were present at the following frequencies: 52.6%, 40.7% and 6.7%, respectively. CONCLUSION: No correlation was observed between the MTHFR gene polymorphism 677 and chromosomal aneuploidy in the Turner Syndrome patients. However, the MTHFR gene polymorphism at position 1298, mainly genotype 1298CC that reduces the enzyme efficiency, was more frequent in the group of Turner Syndrome patients, suggesting its involvement in mechanisms related to chromosomal imbalances.


2006 ◽  
Vol 2 (4) ◽  
pp. 467-476 ◽  
Author(s):  
Bentham Science Publisher Bentham Science Publisher

2006 ◽  
Vol 22 (1) ◽  
pp. 81-81
Author(s):  
S Agrawal ◽  
S Komandur ◽  
RV Alluri ◽  
S Satyanarayana ◽  
VL Phaneeshwar ◽  
...  

2020 ◽  
Vol 40 ◽  
pp. 431
Author(s):  
R. Komsa-Penkova ◽  
B. Dimitrov ◽  
P. Tonchev ◽  
K. Gospodinova ◽  
D. Gospodinov

2005 ◽  
Vol 23 (7) ◽  
pp. 1365-1369 ◽  
Author(s):  
Anders Jakobsen ◽  
Jens Nederby Nielsen ◽  
Niels Gyldenkerne ◽  
Jan Lindeberg

Purpose To analyze thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with respect to fluorouracil (FU) sensitivity. Patients and Methods The study included a retrospective analysis of 88 patients with metastatic colorectal cancer and a prospective trial with 51 patients also with measurable metastases. All patients were treated with FU and leucovorin. The analysis of gene polymorphism was performed on normal intestinal tissue and lymphocytes. Results The response rate was significantly higher in patients with TS 3R/3R or MTHFR 677 TT gene polymorphism compared with the other groups. The difference of response rate translated to a difference in time to progression. Similar results were observed in the retrospective analysis and the prospective confirmatory trial. Conclusion The analysis of gene polymorphism allows delineation of a group of patients (30%) with a response rate to a single drug of approximately 50%. This information should be used in the design of tailored treatment.


2018 ◽  
Vol 12_2018 ◽  
pp. 23-28
Author(s):  
Tyutyunnik V.L. Tyutyunnik ◽  
Kan N.E. Kan ◽  
Mantrova D.A. Mantrova ◽  
Lomova N.A. Lomova N ◽  
Klimantsev I.V. Klimantsev ◽  
...  

2001 ◽  
Vol 1 (5) ◽  
pp. 353-361 ◽  
Author(s):  
Kenji Nakai ◽  
Chuichi Itoh ◽  
Keiko Nakai ◽  
Wataru Habano ◽  
David Gurwitz

Sign in / Sign up

Export Citation Format

Share Document